摘要
On the eve of 2021,China's National Health Commission anno unced that the domestically produced Sinopharm COVID-19 vaccine would be free to the Chinese public.High-risk groups were given priority but the first few months of thear saw an unprecedented roll-out of the global vaccination campaign.
